


# GALLIMUNE<sup>®</sup> FLU H5N9

The Inactivated Solution for AI Control. Proven Safe and Effective.

# FACT

S h e e t



THE RESPIRATORY SHIELD and THE PERFORMANCE BUILDER are trademarks of Merial. ©1999-2004 Merial Select, Gainesville, Georgia. All rights reserved. GALLIMUNE is a registered trademark of Merial Inc. Corporation Georgia, Athens Georgia ©2002-2004

# The Inactivated Solution for AI Control. Proven Safe and Effective.

## Characteristics of Gallimune® Flu H5N9

- Proven, inactivated vaccine technology
- Developed from a strain tested at independent laboratories in the USA and Australia
- Complies with OIE guidelines
- Developed in response to the Asian AI outbreaks

## Features & Benefits

- Contains H5N9 strain of AI
- The hemagglutinin type that is involved in the current Asian outbreak
- An unusual neuraminidase type that differs from the field strains in the current Asian outbreak
- Allows use of the neuraminidase based DIVA testing methodology
- Uses a 0.2 ml dose in broilers and a 0.3 ml dose in pullets
- Low volume dose for easier, more accurate vaccine administration
- Made with a well characterized low pathogenic AI strain
- As recommended in OIE guidelines
- Safer than unregulated vaccines made from highly pathogenic or uncharacterized AI strains



## Serological Response to Gallimune® Flu H5N9

Charts 1 & 2 to the right demonstrate the serological response to Gallimune Flu H5N9.

### Materials & Methods

- SPF chickens were used
- Groups 1 & 2 (G1, G2) were vaccinated at 21-28 days old with 0.3ml dose of Gallimune Flu H5N9 intramuscularly
- Group 3 (G3) were unvaccinated controls
- Serum samples were collected at 28 days post vaccination
- Hemagglutination Inhibition tests were performed using homologous H5N9 hemagglutinating antigen

### Results

All vaccinated chickens showed a satisfactory serological response with a geometric mean titre (GMT) of 256 (8.0 log<sub>2</sub>) or greater (Chart 1). 90% or more of the vaccinated

birds had a titre equal to or greater than the GMT (Chart 2). All of the unvaccinated control birds remained serologically negative.

### Conclusions

Gallimune Flu H5N9 was shown to be potent based on serological response.

Chart 1 – Geometric Mean Titre (log<sub>2</sub>)





Chart 2 – Percentage Positive at Serial Dilutions



## Recommended Vaccination Program

Bird Type	First Vaccination	Second Vaccination	Third Vaccination
BROILERS	Around 7 days	N/A	N/A
PULLETS (in a low challenge area)	Around 7 days	2 – 4 weeks prior to onset of lay	N/A
PULLETS (in a high challenge area)	Around 7 days	6 – 8 weeks prior to onset of lay	2 – 4 weeks prior to onset of lay



AVIAN GLOBAL ENTERPRISE  
 Merial Asia Pte. Ltd.  
 57A Science Park Drive, The Faraday  
 Singapore Science Park 1  
 Singapore 118238  
 Tel: (65).6778.5977 Fax: (65).6776.6903